Dosis repetidas de daclizumab para retrasar la instauración del inhibidor de la calcineurina en pacientes con trasplante cardiaco y disfunción renal postoperatoria

Lázaro, Ignacio J. Sánchez; Bonet, Luis Almenar; Dolz, Luis Martínez; Fuentes, Francisco Buendía; Manchón, Josep Navarro; Ramón-Llin, Jaime Agüero; Sánchez, José Luis Vicente; Sanz, Antonio Salvador

doi:10.1016/j.recesp.2010.05.001

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, there is no gold standard protocol for the management of ARD after HTx. During the early postoperative period, CNI introduction can be delayed and/or started at low doses under MAb coverage ( 7 , 8 ). When ARD appears after the postoperative period, temporary CNI discontinuation with MAb coverage (CNI “holiday”) has been proved effective, allowing the reintroduction of immunosuppressive therapy when renal function is recovered ( 9 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of a “CNI Holidays” Strategy in Acute Renal Dysfunction Late after Heart Transplant. Report of Two Cases

Alonso

Sánchez‐Lázaro

Almenar

et al. 2014

Heart International

View full text Add to dashboard Cite

BackgroundAcute renal dysfunction (ARD) may appear in heart transplant (HTx) patients both in the early postoperative period and during follow-up, even after several years. CD25 is a subunit of the interleukin-2 receptor which is found exclusively on activated CD4 T lymphocytes. CD25 is crucial for clonal expansion of anti-allograft host lymphocytes that mediate in acute rejection. There are experiences supporting the use of Anti-CD25 monoclonal antibodies (MAb) immediately after HTx in patients with ARD as a bridge to renal function recovery, allowing the temporary suspension of treatment with CNI.MethodsIn this study we report two cases of successful use of weekly MAb (basiliximab) in HTx patients who developed late ARD after HTx.ConclusionsIn coclusion, we think that in cases of ARD where CNI therapy plays a key role, the use of weekly doses of basiliximab allows CNI discontinuation until the restoration of renal function is achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

“…We reported our experience with daclizumab use to provide temporary discontinuation of CNI in the setting of ARD immediately after HTx ( 8 ). In these patients we used an empiric weekly dose of daclizumab.…”

Section: Discussionmentioning

confidence: 99%